

Tenth Annual



**Celgene**

*Celebration of Hope Award Recipient*

At Celgene we are changing the course of human health through bold pursuits in science and a promise to always put patients first. The results are evident; we are delivering what matters most: a meaningful difference in the lives of patients worldwide. We discover, develop and deliver innovative medicines that are helping patients live longer and better lives, reducing the burden on healthcare systems and helping economies grow through greater productivity. In recent years we have seen expanded approvals for our flagship therapeutics based on unique mechanisms of action that differentiate them from other approved medications.

Along with our partners, we are involved in a deep and diverse platform of transformational science including immunotherapies, epigenetics, protein homeostasis, cancer metabolism, genomics, proteomics, kinase inhibitors, cellular therapies and beyond. As of the end of 2014, our broad and deep pipeline of 22 programs in clinical development touches roughly 28,000 patients across 50 indications. More than 100 clinical trials are under our development and we support more than 500 investigator-initiated trials using approved therapies or investigational compounds from Celgene. These are the hallmarks of a biopharmaceutical leader that not only serves patients, but a company that serves the changing model of healthcare and the needs of society, with a purpose to change the course of health through medical innovation.

